1,360 Shares in Edwards Lifesciences Corporation $EW Acquired by Catalyst Capital Advisors LLC

Catalyst Capital Advisors LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,360 shares of the medical research company’s stock, valued at approximately $106,000.

Other large investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC increased its stake in Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after buying an additional 145 shares during the period. Pacific Capital Partners Ltd purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $1,760,000. Czech National Bank increased its position in shares of Edwards Lifesciences by 5.8% in the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after purchasing an additional 7,917 shares during the last quarter. Mirova US LLC increased its position in shares of Edwards Lifesciences by 56.2% in the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after purchasing an additional 1,054,301 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Edwards Lifesciences by 111.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 163,202 shares of the medical research company’s stock valued at $12,532,000 after purchasing an additional 86,186 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on EW shares. Mizuho increased their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Piper Sandler increased their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, July 25th. The Goldman Sachs Group reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Finally, Evercore ISI set a $88.00 target price on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $87.06.

Edwards Lifesciences Trading Down 0.5%

Shares of Edwards Lifesciences stock opened at $76.15 on Friday. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company has a market capitalization of $44.70 billion, a P/E ratio of 10.96, a PEG ratio of 3.65 and a beta of 1.05. The company’s fifty day moving average is $77.37 and its two-hundred day moving average is $76.43.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the firm posted $0.70 EPS. Edwards Lifesciences’s revenue for the quarter was up 11.9% on a year-over-year basis. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.